Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avecho Biotechnology Ord Shs V.AVE


Primary Symbol: AVEFF

Healthcare
Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company develops and commercializes human and animal health products using its drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from vitamin E using patented processes. The Company's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The Company's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol and Veterinary Applications. The Company is also developing TPM to enhance feed efficiency and the health of livestock. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.


OTCPK:AVEFF - Post by User

Avecho Biotechnology Ord Shs
Bullboard Posts
User Avatar Image
(1)
•••
Post by benji1on Aug 16, 2017 9:40pm
232 Views
Post# 26590241

Trump Admistration About To Radically Change Nafta

Trump Admistration About To Radically Change NaftaMost of the 52 million dollars is generated in the USA.
AVE will only grow, if NAFTA is changed to assist our friends to the South.

This text was taken from the news earlier today.

“With more than 90% of revenue generated from our U.S. operations, our high level exposure to the U.S. market has helped to produce record results for the company,’’ said Aveda CEO Ronnie Witherspoon. “We have captured new business opportunities as rig counts continued to increase in every U.S. basin in which we operate,’’ he said.
Read more at https://www.stockhouse.com/news/newswire/2017/08/16/aveda-transportation-sees-500-revenue-increase-q2#2dS1sDBBmx3DgadL.99


Also Canada BUYS just changed there rating from a short to BUY on AVE.


 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities